Somei Ura

Somei Ura

Auto-generated profile, based on publicly available information

Somei Ura

Department of Education and Research, Instituto Lauro de Souza Lima, Rod. Cte João Ribeiro de Barros, km 225/26, Bauru, SP, CEP: 17039-800, Brazil.

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2009 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
PRPatricia Sammarco Rosa
Patricia Sammarco Rosa
CSCleverson Teixeira Soares
Cleverson Teixeira Soares
ABAndréa de Faria Fernandes Belone
Andréa de Faria Fernandes Belone
RVRaquel Vilela
Raquel Vilela
SUSomei Ura
Somei Ura
LMLeonel Mendoza
Leonel Mendoza
Jorge Lobo's disease (Lacaziosis) is a subcutaneous infection of humans living in the Amazon region of Latin America, and in dolphins inhabiting the east coastal areas of the United States. The disease mainly affects people from rural areas living or working in close contact with vegetation and aquatic environments. Most patients refer having developed lesions after accidental trauma with plant thorns or insect bites. Inter-human transmission has never been confirmed suggesting that Lacazia loboi is acquired from environmental propagules.

21 January 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
FSFabiana Covolo de Souza-Santana
Fabiana Covolo de Souza-Santana
EMElaine V Camarinha Marcos
Elaine V Camarinha Marcos
MNMaria Esther Salles Nogueira
Maria Esther Salles Nogueira
SUSomei Ura
Somei Ura
JTJane Tomimori
Jane Tomimori
Evidence suggests that human leukocyte antigen (HLA) alleles influence the host immune response against Mycobacterium leprae. However, the association between HLA alleles and borderline (B) leprosy has not been studied. The aim of this study was to determine whether HLA class I and II molecules are associated with susceptibility or resistance to B leprosy including borderline-tuberculoid (BT), borderline-borderline (BB), and borderline-lepromatous (BL). DNA was obtained by the salting-out technique from the blood samples of 202 patients with B leprosy and 478 control subjects. HLA class I (A*, B*, and C* loci) and class II (DRB1* and DQB1* loci) genotypes were determined by polymerase chain reaction amplification and reverse hybridization with sequence-specific oligonucleotide probes and sequence-specific primers. The case-controlled analysis results showed a significant association between B leprosy and HLA-C*05 (5.94% vs. 14.02%; p = 0.002, OR = 0.38, 95% CI = 0.20–0.73, pc = 0.032) and HLA-DRB1*07 (16.34% vs. 26.77%; p = 0.003, OR = 0.53, 95% CI = 0.3–0.8, pc = 0.039). A protective association was observed between BL leprosy and HLA-DQB1*02 (18.18% vs. 39.53%; p = 0.005, OR = 0.34, 95% CI = 0.15–0.75, pc = 0.025). In reactional patients, a significant association was observed between HLA-B*15 (28.72% vs. 12.76%; p = 0.011, OR = 2.75, 95% CI = 1.30–5.85, pc = 0.352) and predisposition to reversal reaction. Haplotype analysis showed that A*02-B*07-C*07-DRB1*15-DQB1*06 (2.97% vs. 1.04%; p = 0.015) and A*02-B*40-C*03-DRB1*13-DQB1*06 (1.73% vs. 0.10%; p = 0.0011) were associated with susceptibility to the B form. The presence of the HLA-DRB1*02 or HLA-DRB1*03/HLA-DQB1*01 haplotypes in B patients (22.05% vs. 33.0%; p = 0.005) suggested the involvement of these haplotypes in this clinical form of the disease. The results indicate the involvement of HLA class I and class II molecules in B leprosy and reversal reactions; it also suggest a role for HLA in polarization of the disease in this group of patients.

1 September 1995 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
MAMaria Sueli Parreira de Arruda
Maria Sueli Parreira de Arruda
RFRaul Negrão Fleury
Raul Negrão Fleury
MNMaria Esther Salles Nogueira
Maria Esther Salles Nogueira
SUSomei Ura
Somei Ura
OAOlavo Speranza de Arruda
Olavo Speranza de Arruda
Neste estudo investigou-se o potencial imunomodulador do levamisole e da mistura BCG/Mycobacterium leprae em pacientes virchovianos inativos, utilizando como parâmetro a reação de Mitsuda. Vinte pacientes, classificados como Mitsuda histologicamente negativos há 10 anos, foram divididos em três grupos: cinco pacientes que foram somente reavaliados frente a mitsudina: oito pacientes que receberam levamisole e, sete que receberam a mistura de BCG vivo mais M. leprae morto. Os resultados mostraram que: 1) o levamisole não alterou a reatividade à mitsudina em nenhum dos casos estudados; 2) as modificações da reatividade verificadas com o uso da mistura (tres casos) ou aquelas que ocorreram espontaneamente (tres casos) foram sempre de pequena amplitude e refletiram variações próprias de pacientes com algum grau de resistência ao Mycobacterium leprae.